Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives

Sclerostin emerges as a novel target for bone anabolic therapy in bone diseases. Osteogenesis imperfecta (OI) and X-linked hypophosphatemia (XLH) are rare bone diseases in which therapeutic potential of sclerostin inhibition cannot be ignored. In OI, genetic/pharmacologic sclerostin inhibition promo...

Full description

Bibliographic Details

Published in:	Journal of Orthopaedic Translation
Main Authors:	Tao Xiaohui, Luyao Wang, Xin Yang, Hewen Jiang, Ning Zhang, Huarui Zhang, Dijie Li, Xiaofei Li, Yihao Zhang, Shenghang Wang, Chuanxin Zhong, Sifan Yu, Meishen Ren, Meiheng Sun, Nanxi Li, Tienan Chen, Yuan Ma, Fangfei Li, Jin Liu, Yuanyuan Yu, Hua Yue, Zhenlin Zhang, Ge Zhang
Format:	Article
Language:	English
Published:	Elsevier 2024-07-01
Subjects:	Cardiovascular safety Loops Osteogenesis imperfecta (OI) Sclerostin Sclerostin inhibition Therapeutic perspectives
Online Access:	http://www.sciencedirect.com/science/article/pii/S2214031X24000469